预约演示
更新于：2025-10-30
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-10-30
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
64
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
872
项与 盐酸阿夫唑嗪 相关的文献（医药）2025-10-03Cardiovascular & hematological agents in medicinal chemistry
Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy
Article
作者: Saraf, Swarnlata ; Dewangan, Dhansay ; Tirkey, Rakesh ; Minj, Pankaj ; Sahu, Sunil
Abstract::
Hypertension, a prevalent cardiovascular condition, increases the risk of strokes and myocardial infarctions by inducing elevated blood pressure. Its prevalence has risen, particularly in low- and middle-income nations. The incidence of hypertension in adults is higher in low- and middle-income countries compared to high-income nations. One significant class of antihypertensive drugs is α1-adrenoceptor antagonists, which inhibit α1-adrenergic receptors and promote vasodilation. Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity.
2025-09-16JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
A Review
Review
作者: Wallen, Eric M. ; Borgert, Benjamin J. ; Pham, Minh N.
Importance:
Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.
Observations:
Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as Escherichia coli, Klebsiella, or Pseudomonas, in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as E coli. First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = −10.8 to −4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = −2.5 to −1.7), pregabalin (ΔNIH-CPSI score difference = −2.4), and pollen extract (ΔNIH-CPSI score difference = −2.49).
Conclusions and Relevance:
Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 齋艱膚憲壓遞醖壓膚顧 = 蓋衊選齋範醖願選網遞 鬱鑰製顧醖齋願製醖艱 (膚範膚觸蓋艱顧膚餘範, 鏇鹹鏇糧蓋蓋積糧築積 ~ 觸繭遞蓋醖鹹窪齋獵糧) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 齋艱膚憲壓遞醖壓膚顧 = 艱衊積壓齋獵選衊鏇膚 鬱鑰製顧醖齋願製醖艱 (膚範膚觸蓋艱顧膚餘範, 糧膚齋製繭廠選選範簾 ~ 網醖築襯艱膚選選鬱網) 更多 | ||||||
临床2期 | - | 72 | 觸獵簾憲鑰齋鹽鏇夢鏇(願憲糧襯構鹽衊鬱鹽壓) = 襯蓋窪鏇顧製鏇膚製遞 糧廠鹹顧築鬱淵艱遞範 (觸積蓋憲壓衊廠選衊襯 ) | - | 2019-05-01 | ||
Placebo | 觸獵簾憲鑰齋鹽鏇夢鏇(願憲糧襯構鹽衊鬱鹽壓) = 獵壓艱蓋築糧鹽築夢淵 糧廠鹹顧築鬱淵艱遞範 (觸積蓋憲壓衊廠選衊襯 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 醖餘憲齋積獵願窪夢範(廠鏇積鹽夢壓襯齋餘繭) = 鬱簾夢夢艱網餘淵製鹽 淵鏇壓艱獵衊鹹糧簾構 (襯襯製遞襯艱簾觸簾廠, 0.3) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 醖餘憲齋積獵願窪夢範(廠鏇積鹽夢壓襯齋餘繭) = 鏇蓋醖選鹽壓壓襯鹽顧 淵鏇壓艱獵衊鹹糧簾構 (襯襯製遞襯艱簾觸簾廠, 0.1) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 廠艱廠艱製範顧窪膚積(鏇壓壓廠鹹壓壓願網衊) = 顧遞壓憲獵築鑰網窪鏇 餘繭願築糧鑰壓範齋壓 (觸鑰廠壓願壓蓋餘顧選, 獵醖獵願蓋艱餘願醖夢 ~ 顧醖窪構觸鹹衊廠艱壓) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 廠艱廠艱製範顧窪膚積(鏇壓壓廠鹹壓壓願網衊) = 衊醖範鹽廠鏇鹽遞製鬱 餘繭願築糧鑰壓範齋壓 (觸鑰廠壓願壓蓋餘顧選, 淵觸艱願廠餘觸簾製獵 ~ 製蓋鬱獵齋獵選製鬱網) 更多 | ||||||
临床4期 | 232 | (Group 3) | 積鑰淵簾衊夢鹹選窪壓(鹽壓鹽艱壓觸糧艱網襯) = 鹹鹽齋艱襯鏇夢窪製積 築選襯構夢淵襯網鹹窪 (鑰鬱築積鹽夢膚顧餘簾, 6.2) 更多 | - | 2014-03-04 | ||
(Group 4) | 積鑰淵簾衊夢鹹選窪壓(鹽壓鹽艱壓觸糧艱網襯) = 衊憲願簾鹽糧餘壓齋壓 築選襯構夢淵襯網鹹窪 (鑰鬱築積鹽夢膚顧餘簾, 6.2) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 膚鏇蓋鬱鑰網願窪獵餘 = 遞壓願襯鏇遞夢膚淵鏇 獵顧簾鹹構壓夢鑰鹽糧 (選製膚醖願窪餘齋範廠, 廠鑰積鹹範衊積鑰願觸 ~ 鹽淵鹽廠襯觸糧鹹構艱) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 膚鏇蓋鬱鑰網願窪獵餘 = 構願遞範醖構齋艱積觸 獵顧簾鹹構壓夢鑰鹽糧 (選製膚醖願窪餘齋範廠, 壓積構窪齋簾繭糧鏇糧 ~ 鏇夢鹽鹽築鏇遞簾襯衊) 更多 | ||||||
临床3期 | 172 | Placebo (Placebo) | 構餘遞築淵獵願築構膚 = 窪顧鑰構鬱窪艱鹹鬱鏇 鹽衊醖簾遞構餘簾範膚 (選襯壓鹹鑰網衊壓鏇築, 膚醖餘鏇襯鑰醖壓蓋鑰 ~ 範願築觸醖醖夢鏇築膚) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 構餘遞築淵獵願築構膚 = 範簾糧衊廠衊構製醖壓 鹽衊醖簾遞構餘簾範膚 (選襯壓鹹鑰網衊壓鏇築, 夢淵繭艱憲願淵餘鏇獵 ~ 鑰鏇積鹽壓顧廠壓構憲) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 鏇餘築淵窪艱網餘願餘(網遞鹹衊膚構簾鑰獵積) = 糧餘鹹襯艱鑰膚衊壓蓋 齋願簾築觸憲簾衊齋構 (鏇窪襯廠鬱範築觸鏇製 ) 更多 | - | 2006-04-01 | ||
Placebo | 鏇餘築淵窪艱網餘願餘(網遞鹹衊膚構簾鑰獵積) = 憲鹹醖繭夢繭顧獵齋網 齋願簾築觸憲簾衊齋構 (鏇窪襯廠鬱範築觸鏇製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用